INmune Bio, Inc.

NASDAQ:INMB

5.46 (USD) • At close September 13, 2024
Bedrijfsnaam INmune Bio, Inc.
Symbool INMB
Munteenheid USD
Prijs 5.46
Beurswaarde 108,011,904
Dividendpercentage 0%
52-weken bereik 5.403 - 14.74
Industrie Biotechnology
Sector Healthcare
CEO Dr. Raymond Joseph Tesi M.D.
Website https://www.inmunebio.com

An error occurred while fetching data.

Over INmune Bio, Inc.

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory

Vergelijkbare Aandelen

Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc.

ATOS

1.52 USD

FONAR Corporation logo

FONAR Corporation

FONR

16.82 USD

Societal CDMO, Inc. logo

Societal CDMO, Inc.

SCTL

1.1 USD

Omega Therapeutics, Inc. logo

Omega Therapeutics, Inc.

OMGA

1.33 USD

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

14.93 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)